• Aditi Kadakia, Carole Dembek, Yi Liu, Christopher Dieyi, and G Rhys Williams.
• Sunovion Pharmaceuticals Inc., Marlborough, MA, USA.
• J Med Econ. 2021 Jan 1; 24 (1): 1212-1220.

BackgroundReal-world evidence on atypical antipsychotic (AAP) use in pediatric bipolar disorder is limited.ObjectiveTo assess the risk of all-cause and psychiatric hospitalization among pediatric patients with bipolar disorder when treated with lurasidone versus other atypical antipsychotics (AAPs).MethodsThis retrospective cohort study used commercial claims data (January 1, 2011 to June 30, 2017) to identify pediatric patients (age ≤17 years) with bipolar disorder treated with oral atypical antipsychotics (N = 16,201). The date of the first claim for an AAP defined the index date, with pre- and post-index periods of 180 days. Each month of the post-index period was categorized as monotherapy treatment with lurasidone, aripiprazole, olanzapine, quetiapine, or risperidone, no/minimal treatment, or other. The risk of all-cause and psychiatric hospitalizations (defined by a psychiatric diagnosis on the facility claim) was analyzed based on treatment in the current month, time-varying covariates (prior treatment-month classification, hospitalization in the prior month, emergency room visit in the prior month), and fixed covariates (age, gender, pervasive development disorder/mental retardation, disruptive behavior/conduct disorder, attention deficit hyperactivity disorder, depression, anxiety, adjustment disorder, obesity, diabetes, antidepressants, anxiolytics, other co-medication) using a marginal structural model.ResultsTreatment with aripiprazole (OR = 1.60, 95% CI: 1.08-2.36) and olanzapine (OR = 1.68, CI: 1.03-2.71) was associated with significantly higher odds of all-cause hospitalizations compared to lurasidone, but treatment with quetiapine (OR = 1.03, CI: 0.69-1.54) or risperidone (OR = 1.02, CI: 0.68-1.53) was not. Similarly, treatment with aripiprazole (OR = 1.61, 95% CI: 1.08-2.38) and olanzapine (OR = 1.73, CI: 1.06-2.80) was associated with significantly higher odds of psychiatric hospitalizations compared to lurasidone, but treatment with quetiapine (OR = 1.02, CI: 0.68-1.54) or risperidone (OR = 1.01, CI: 0.67-1.51) was not.ConclusionIn usual clinical care, pediatric patients with bipolar disorder treated with lurasidone had a significantly lower risk of all-cause and psychiatric hospitalizations when compared to aripiprazole and olanzapine, but not quetiapine or risperidone.

17 keywords...

hide…